Inhaled Drugs and Systemic Corticosteroids for Bronchopulmonary Dysplasia

被引：7

作者：

Bassler, Dirk ^{[1
]}

van den Anker, John ^{[2
,3
]}

机构：

[1] Univ Zurich, Univ Hosp Zurich, Dept Neonatol, Frauenklin Str 10, CH-8091 Zurich, Switzerland

[2] Univ Basel, Div Paediat Pharmacol & Pharmacometr, Childrens Hosp, Spitalstr 33, CH-4056 Basel, Switzerland

[3] Childrens Natl Med Ctr, Div Clin Pharmacol, 111 Michigan Ave NorthWest, Washington, DC 20010 USA

来源：

PEDIATRIC CLINICS OF NORTH AMERICA | 2017年 / 64卷 / 06期

关键词：

Bronchopulmonary dysplasia; Inhaled corticosteroids; Inhaled bronchodilators; Systemic corticosteroids; Dexamethasone; Hydrocortisone; Pharmacology; CHRONIC LUNG-DISEASE; LOW-DOSE HYDROCORTISONE; PRETERM INFANTS; PREMATURE-INFANTS; RANDOMIZED-TRIAL; CEREBRAL-PALSY; DOUBLE-BLIND; PREVENTION; THERAPY; PHARMACOKINETICS;

D O I：

10.1016/j.pcl.2017.08.012

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

All definitions of bronchopulmonary dysplasia (BPD) have limitations, and a new definition for the purpose of clinical research, benchmarking, and prognostic prediction is needed. Different inhaled and systemic drugs are currently used to prevent or treat BPD. Despite some positive effects on BPD, more information about the effects of inhaled corticosteroids is required to assess overall efficacy and associated risks. One needs to balance the risks of neurodevelopmental impairment owing to systemic corticosteroids against those of BPD itself. Future studies should, therefore, focus on infants with a very high risk of developing BPD and include pharmacokinetics and long-term developmental outcomes.

引用

页码：1355 / +

页数：14

共 50 条

[21] Inhaled budesonide in bronchopulmonary dysplasia
Yaqub, Farhat
LANCET RESPIRATORY MEDICINE, 2015, 3 (12): : 926 - 926
[22] Inhaled Corticosteroids Were Associated with a Longer Duration of Home Oxygen in Infants with Bronchopulmonary Dysplasia
Dawson, S.
D'Andrea, L. A.
Lagatta, J.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
[23] Corticosteroids in the prevention and treatment of infants with bronchopulmonary dysplasia: Part II. Inhaled corticosteroids alone or in combination with surfactants
Szabo, Hajnalka
Baraldi, Eugenio
Colin, Andrew A.
PEDIATRIC PULMONOLOGY, 2022, 57 (04) : 787 - 795
[24] Systemic Corticosteroids for the Prevention of Bronchopulmonary Dysplasia: Picking the Right Drug for the Right Baby
Rostas, Sara E.
McPherson, Christopher
NEONATAL NETWORK, 2016, 35 (04): : 234 - 239
[25] Reviewing the use of corticosteroids in bronchopulmonary dysplasia
de Oliveira Peixoto, Fernanda Aparecida
Sucasas Costa, Paulo Sergio
JORNAL DE PEDIATRIA, 2016, 92 (02) : 122 - 128
[26] Postnatal corticosteroids for the prevention of bronchopulmonary dysplasia
Onland, W.
de Jaegere, A. P.
van de Loo, M.
van Kaam, A. H.
NETHERLANDS JOURNAL OF CRITICAL CARE, 2014, 18 (02): : 8 - 14
[27] Corticosteroids for the Treatment and Prevention of Bronchopulmonary Dysplasia
Soll, Roger F.
NEONATOLOGY, 2010, 98 (02) : 109 - 110
[28] Candida pneumonia in a term infant after prolonged use of inhaled corticosteroids for bronchopulmonary dysplasia (BPD)
Buzzi, Eleonora
Manzoni, Paolo
Castagnola, Elio
Benjamin, Daniel K., Jr.
Beghini, Renzo
Dall'agnola, Alberto
EARLY HUMAN DEVELOPMENT, 2013, 89 : S62 - S63
[29] Inhaled Nitric Oxide and Bronchopulmonary Dysplasia
Steinhorn, Robin H.
Shaul, Philip W.
deRegnier, Raye-Ann O.
Kennedy, Kathleen A.
PEDIATRICS, 2011, 128 (01) : E255 - E256
[30] Use of inhaled corticosteroids for the prevention and/or treatment of bronchopulmonary dysplasia in preterm infants: a systematic review protocol
Shinwell, Eric S.
Portnov, Igor
Meerpohl, Joerg
Karen, Tanja
Bassler, Dirk
SYSTEMATIC REVIEWS, 2015, 4

← 1 2 3 4 5 →